BlackRock’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,569,585
| Closed | -$505M | – | 5884 |
|
|
2026
Q1 | $505M | Buy |
9,569,585
+1,375,367
| +17% | +$56.5M | 0.01% | 1091 |
|
|
2025
Q4 | $331M | Buy |
8,194,218
+2,642,910
| +48% | +$61.1M | 0.01% | 1371 |
|
|
2025
Q3 | $41.7M | Buy |
5,551,308
+80,934
| +1% | +$517K | ﹤0.01% | 2616 |
|
|
2025
Q2 | $20.4M | Sell |
5,470,374
-236,258
| -4% | -$738K | ﹤0.01% | 3012 |
|
|
2025
Q1 | $15.8M | Sell |
5,706,632
-36,850
| -0.6% | -$150K | ﹤0.01% | 3072 |
|
|
2024
Q4 | $31.8M | Buy |
5,743,482
+1,044,711
| +22% | +$7.07M | ﹤0.01% | 2749 |
|
|
2024
Q3 | $39.2M | Buy |
4,698,771
+578,263
| +14% | +$4.76M | ﹤0.01% | 2629 |
|
|
2024
Q2 | $28.1M | Buy |
4,120,508
+804,979
| +24% | +$4.88M | ﹤0.01% | 2775 |
|
|
2024
Q1 | $21.7M | Sell |
3,315,529
-93,449
| -3% | -$610K | ﹤0.01% | 2949 |
|
|
2023
Q4 | $22.1M | Buy |
3,408,978
+244,163
| +8% | +$1.29M | ﹤0.01% | 2958 |
|
|
2023
Q3 | $15.9M | Buy |
3,164,815
+26,286
| +0.8% | +$167K | ﹤0.01% | 3072 |
|
|
2023
Q2 | $27.5M | Buy |
3,138,529
+2,437,862
| +348% | +$28.4M | ﹤0.01% | 2834 |
|
|
2023
Q1 | $8.3M | Buy |
700,667
+401,229
| +134% | +$3.83M | ﹤0.01% | 3414 |
|
|
2022
Q4 | $3.05M | Buy |
299,438
+13,145
| +5% | +$87.5K | ﹤0.01% | 3947 |
|
|
2022
Q3 | $1.69M | Buy |
286,293
+136,765
| +91% | +$508K | ﹤0.01% | 4274 |
|
|
2022
Q2 | $371K | Sell |
149,528
-587,413
| -80% | -$1.17M | ﹤0.01% | 4864 |
|
|
2022
Q1 | $2.19M | Sell |
736,941
-8,594
| -1% | -$36.7K | ﹤0.01% | 4349 |
|
|
2021
Q4 | $5.27M | Buy |
745,535
+142,979
| +24% | +$1.19M | ﹤0.01% | 3975 |
|
|
2021
Q3 | $6.28M | Buy |
602,556
+164,952
| +38% | +$1.71M | ﹤0.01% | 3869 |
|
|
2021
Q2 | $5.37M | Buy |
437,604
+30,255
| +7% | +$515K | ﹤0.01% | 3849 |
|
|
2021
Q1 | $8.96M | Buy |
+407,349
| New | +$8.93M | ﹤0.01% | 3638 |
|
Other funds holding TERN
BlackRock's TERN Position: Q2 2026 in Review
BlackRock sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 9,569,585 shares — an estimated $505M sold.
BlackRock first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $505M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- BlackRock reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 9,569,585 Terns Pharmaceuticals shares in Q2 2026, an estimated $505M.
- BlackRock first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- BlackRock's Terns Pharmaceuticals position peaked at $505M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.